Neurological symptoms associated with cancer treatment
© 2021. The Author(s)..
Systemic treatment in oncology has become more biomarker-based, molecularly tailored and effective. Building on increasing scientific insights into cell biological and molecular mechanisms, the number of targeted drug therapies is also increasing. There is also an increase in the number of long-term survivors. Neuro(onco)logical care is becoming increasingly more important, not only because of increased direct tumor-related symptoms, such as higher incidence of central nervous system metastases, but also because a broad spectrum of treatment-associated neurological symptoms occur during the course of these modern oncological systemic therapies, which require careful and fast neurological/neuro-oncological evaluation and treatment. The goal of this article is to raise awareness of the most common treatment-associated neurologic symptoms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:92 |
|---|---|
| Enthalten in: |
Der Nervenarzt - 92(2021), 12 vom: 25. Dez., Seite 1305-1314 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Tumortherapieassoziierte neurologische Symptome |
|---|
| Beteiligte Personen: |
Renovanz, Mirjam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Central nervous system |
|---|
| Anmerkungen: |
Date Completed 08.12.2021 Date Revised 12.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00115-021-01223-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333591062 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333591062 | ||
| 003 | DE-627 | ||
| 005 | 20231225221946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00115-021-01223-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1111.xml |
| 035 | |a (DE-627)NLM333591062 | ||
| 035 | |a (NLM)34821945 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Renovanz, Mirjam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neurological symptoms associated with cancer treatment |
| 246 | 3 | 3 | |a Tumortherapieassoziierte neurologische Symptome |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.12.2021 | ||
| 500 | |a Date Revised 12.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a Systemic treatment in oncology has become more biomarker-based, molecularly tailored and effective. Building on increasing scientific insights into cell biological and molecular mechanisms, the number of targeted drug therapies is also increasing. There is also an increase in the number of long-term survivors. Neuro(onco)logical care is becoming increasingly more important, not only because of increased direct tumor-related symptoms, such as higher incidence of central nervous system metastases, but also because a broad spectrum of treatment-associated neurological symptoms occur during the course of these modern oncological systemic therapies, which require careful and fast neurological/neuro-oncological evaluation and treatment. The goal of this article is to raise awareness of the most common treatment-associated neurologic symptoms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Central nervous system | |
| 650 | 4 | |a Encephalopathy | |
| 650 | 4 | |a Myopathy | |
| 650 | 4 | |a Neurotoxicity | |
| 650 | 4 | |a Peripheral nervous system | |
| 700 | 1 | |a Rieger, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Tabatabai, Ghazaleh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Nervenarzt |d 1947 |g 92(2021), 12 vom: 25. Dez., Seite 1305-1314 |w (DE-627)NLM000034320 |x 1433-0407 |7 nnns |
| 773 | 1 | 8 | |g volume:92 |g year:2021 |g number:12 |g day:25 |g month:12 |g pages:1305-1314 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00115-021-01223-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 92 |j 2021 |e 12 |b 25 |c 12 |h 1305-1314 | ||